Astellas Pharma Cash Flow - Annual (OTCMKTS:ALPMY)

Add to My Stocks
$17.81 $0.31 (1.77%) ALPMY stock closing price Sep 19, 2018 (Closing)

The Astellas Pharma cash flow statement helps investors understand how well the company is managing its cash flows. The profit-loss statement shows Astellas Pharma profits, the balance sheet shows Astellas Pharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Astellas Pharma stock analysis. Astellas Pharma had a positive net income cash flow of $2.52B for the latest 2017. This report is very useful in measuring the short term viability of a company. The cash from operating activities for Astellas Pharma is $ 2017, which saw a decrease from previous year.

View details of Astellas Pharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Apr - Mar201720162015201420132012
Net Income Cash Flow
2.52B2.17B1.73B1.18B1.33B1.55B
Depreciation Depletion Amortization Cash-Flow570M574.26M595.81M624M615M799M
Net Increase (Decrease) in Assets Liabilities-53M-1.25B-461.67M-578M-708M272M
Cash From (used in) Discontinued Operations------
Other Adjustments Net-929M1.1B-152.31M849M301M-515M
Net Cash from (used by) Operating Activities
2.1B2.6B1.71B2.08B1.53B2.11B
Increase (Decrease) in Prop Plant And Equipment-248M-263.59M-170.25M-200M-325M-435M
Acquisition Disposition of Subsidiaires-455M-354.01M-181M--46M
Increase (Decrease) in Investments252M132.78M56.01M58M224M180M
Other Cash Inflow (Outflow) from Investment Activities-204M-735.67M-536.19M-299M-416M-16M
Net Cash from (used by) Investment Activities
-655M-1.22B-650.43M-261M-517M-317M
Issuance (Purchase) of Equity Shares-823M-997.05M-529.88M-292M-525M-
Issuance (Repayment) of Debt Securities------
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions-626M-577.8M-565.52M-569M-639M-704M
Other Cash from (used by) Financing Activities-34M-31M-6.77M-6M-3M-3M
Net Cash from (used by) Financing Activities
-1.48B-1.61B-1.1B-868M-1.17B-707M
Effect of Exchange Rate Changes on Cash-136M-79.75M90.69M276M283M-144M
Net Change in Cash & Cash Equivalents
-171M-302.12M46.01M1.23B133M938M
Cash & Equivalents at Beginning of Year3.22B3.29B3.56B2.57B2.69B2.14B
Cash & Equivalents at Year End3.04B2.99B3.61B3.8B2.82B3.08B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Astellas Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Astellas Pharma stock price history.
The statement of cash flows can be categorized into three main sections:

  • Astellas Pharma had a Net Change in Cash and Cash Equivalents of $-171M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Astellas Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a positive value of $2.1B for ALPMY.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-655M for ALPMY stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash flow from financing activities shows the flow of cash between Astellas Pharma and its owners and creditors and was $-1.48B for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Astellas Pharma Cash Flow

FCF margin
0.14

Annual Cash Flow Statements For ASTELLAS PHARMA UNSP ADR EACH REPR 0.25 ORD Peers

Astrazeneca cash flow, Eisai cash flow, Pfizer cash flow, Shire cash flow, Zoetis cash flow